SCHEMBL4189009

SCHEMBL4189009

CC1([C]=O)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HPGD P15428 1/20 0.43
▸ EPHX2 P34913 1/20 0.42
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118226 0.85 USP2 (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL15207180 0.85 USP2 (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL3436829 0.82 USP2 (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL78071 0.80 USP2 (0.55) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL3334222 0.79 USP2 (0.46) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL22983897 0.79 USP2 (0.42) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL22983705 0.79 USP2 (0.42) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL22088545 0.79 USP2 (0.42) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL28587335 0.79 VNN1 (0.46) USP2SMN1; SMN2HPGDEPHX2ALDH1A1
SCHEMBL28604412 0.79 VNN1 (0.46) USP2SMN1; SMN2HPGDEPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-11-05 — — US claimed
EP-2032559-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2009-03-11 — — EP claimed
WO-2007138268-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2007-12-06 — — WO claimed
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION CCNI, MKI67, CDK2 USP2 3279/4885SMN1; SMN2 1708/4885HPGD 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback